Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine

    NEXT STORY
    Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046
    PREV STORY
    NextCure Presents Biomarker Data and Updated Clinical Results from Phase 1 Portion of its NC318 Clinical Trial at the 2020 Virtual American Society of Clinical Oncology Annual Meeting
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia

    author_avatar
    NASDAQ Market News

    Adaptimmune Provides Update on Study of NY-ESO SPEAR® T-cell Therapy in Synovial Sarcoma at the European Society for Medical Oncology (ESMO) 2016 Congress

    PHILADELPHIA and OXFORD, United Kingdom, Oct. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc ...

    author_avatar
    NASDAQ Market News

    RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults

    author_avatar
    NASDAQ Market News